Recent Advances and Future Perspectives of Microbial Metabolites: Applications in Biomedicine

358 Pages·2022·5.278 MB·English

by  Surajit De Mandal, Xiaoxia Xu, Fengliang Jin, Amrita Kumari Panda, K. Syed Ibrahim

R A
ECENT DVANCES AND
F P
UTURE ERSPECTIVES OF
M M
ICROBIAL ETABOLITES
This pageintentionallyleftblank
R A
ECENT DVANCES AND
F P
UTURE ERSPECTIVES OF
M M
ICROBIAL ETABOLITES
Applications in Biomedicine
Edited by
SURAJIT DE MANDAL
College of Plant Protection, South China Agricultural
University, Guangzhou, P.R. China
XIAOXIA XU
College of Plant Protection, South China Agricultural
University, Guangzhou, P.R. China
FENGLIANG JIN
College of Plant Protection, South China Agricultural
University, Guangzhou, P.R. China
AMRITA KUMARI PANDA
Department of Biotechnology, Sant Gahira Guru
University, Ambikapur, Chhattisgarh, India
KALIBULLA SYED IBRAHIM
PG & Research Department of Botany, PSG College of Arts
& Science, Coimbatore, Tamil Nadu, India
AcademicPressisanimprintofElsevier
125LondonWall,LondonEC2Y5AS,UnitedKingdom
525BStreet,Suite1650,SanDiego,CA92101,UnitedStates
50HampshireStreet,5thFloor,Cambridge,MA02139,UnitedStates
TheBoulevard,LangfordLane,Kidlington,OxfordOX51GB,UnitedKingdom
Copyright©2023ElsevierInc.Allrightsreserved.
Nopartofthispublicationmaybereproducedortransmittedinanyformorbyanymeans,
electronicormechanical,includingphotocopying,recording,oranyinformationstorageand
retrievalsystem,withoutpermissioninwritingfromthepublisher.Detailsonhowtoseek
permission,furtherinformationaboutthePublisher’spermissionspoliciesandour
arrangementswithorganizationssuchastheCopyrightClearanceCenterandtheCopyright
LicensingAgency,canbefoundatourwebsite:www.elsevier.com/permissions.
Thisbookandtheindividualcontributionscontainedinitareprotectedundercopyrightby
thePublisher(otherthanasmaybenotedherein).
Notices
Knowledgeandbestpracticeinthisfieldareconstantlychanging.Asnewresearchand
experiencebroadenourunderstanding,changesinresearchmethods,professionalpractices,
ormedicaltreatmentmaybecomenecessary.
Practitionersandresearchersmustalwaysrelyontheirownexperienceandknowledgein
evaluatingandusinganyinformation,methods,compounds,orexperimentsdescribed
herein.Inusingsuchinformationormethodstheyshouldbemindfuloftheirownsafety
andthesafetyofothers,includingpartiesforwhomtheyhaveaprofessionalresponsibility.
Tothefullestextentofthelaw,neitherthePublishernortheauthors,contributors,or
editors,assumeanyliabilityforanyinjuryand/ordamagetopersonsorpropertyasamatter
ofproductsliability,negligenceorotherwise,orfromanyuseoroperationofanymethods,
products,instructions,orideascontainedinthematerialherein.
ISBN:978-0-323-90113-0
ForInformationonallAcademicPresspublications
visitourwebsiteathttps://www.elsevier.com/books-and-journals
Publisher:StacyMasucci
AcquisitionsEditor:LindaVersteeg-Buschman
EditorialProjectManager:ZsereenaRoseMampusti
ProductionProjectManager:NiranjanBhaskaran
CoverDesigner:GregHarris
TypesetbyMPSLimited,Chennai,India
Contents
Listofcontributors xi
Abouttheeditors xv
1. The therapeutic role ofmicrobial metabolites in human
health and diseases 1
NiveditaManoharan,RajeshwariParasuraman,DheepthiJayamuraliand
SathyaNarayananGovindarajulu
1.1 Background 1
1.2 Modeofactionofmicrobialmetabolites 4
1.2.1 Diabetesmellitus 4
1.2.2 Cardiovasculardisease 5
1.2.3 Neurologicaldisorder 7
1.2.4 Gastrointestinaldisorder 8
1.2.5 Colorectalcancer 9
1.3 Therapeuticaleffectsofmicrobialmetabolitesinhumanhealthanddiseases 10
1.3.1 Short-chainfattyacid 10
1.3.2 Bileacids 11
1.3.3 Imidazolepropionate 12
1.3.4 TrimethylamineN-oxide 12
1.3.5 4-Ethylphenylsulfate 13
1.3.6 N-Acylamides 13
1.3.7 Branched-chainaminoacids 14
1.3.8 Long-chainfattyacids 14
1.3.9 Indolederivativemetabolites 15
1.3.10 Taurine 16
1.3.11 Desaminotyrosine 16
1.3.12 Retionicacid 16
1.3.13 Polyamines 17
1.4 Conclusion 17
References 23
2. Peptideswith therapeutic applications from microbial origin 39
KalibullaSyedIbrahim,RangasamyKarthika,NandhakumarDivyaa,
JayasekarMoniushaandRajkumarPraveen
2.1 Introduction 39
2.2 Substratesforpeptideproduction 40
v
vi Contents
2.3 Methodsinpeptideproduction 41
2.4 Hydrolysisbyenzyme 41
2.5 Microbialfermentation 42
2.6 Computationalapproach 43
2.7 Hybridapproach 43
2.8 Pharmacologicalpropertiesofmicrobialpeptides 43
2.9 Pharmacologicalpropertiesofbacterialpeptides 44
2.10 Pharmacologicalpropertiesoffungalpeptides 45
2.11 Pharmacologicalpropertiesofyeastpeptides 47
2.12 Challenges 48
2.13 Conclusionandfutureperspectivesofbioactivepeptides 49
References 51
3. Current status of microbial lectinsinbiomedical research 59
RojitaMishra,RashiMiglani,KulbhusanKumar,AmritaKumariPanda,
SurajitDeMandal,MahendraRanaandSatpalSinghBisht
3.1 Introduction 59
3.2 Typesofmicrobiallectins 60
3.3 Characterizationoflectins 61
3.4 Applicationoflectinsinbiomedicalresearch 62
3.4.1 Antibiofilmandantibacterialactivity 62
3.4.2 Biosensor 65
3.4.3 Cancerdiagnosisandcancertherapy 66
3.4.4 Antinociceptiveactivity 67
3.4.5 Anti-inflammatoryactivity 68
3.4.6 Antiviralactivity 68
3.4.7 Antioxidantactivity 71
3.4.8 Lectibodies 71
3.4.9 Multifariousapplications 72
3.5 Conclusion 72
Reference 73
4. Current trendsand future perspectivesof probioticson
humanhealth: an overview 81
SuchetaMandalandNarayanChandraMandal
4.1 Introduction 81
4.2 Historyanddevelopmentofprobiotics 83
4.3 Beneficialactivitiesofprobiotics 85
4.3.1 Problemsrelatedtothedigestivetract 85
Contents vii
4.3.2 Obesity 96
4.3.3 Diabetes 98
4.3.4 Allergy 99
4.3.5 Urogenitalhealthcare 100
4.3.6 Centralnervoussystem 100
4.3.7 Bonediseases 101
4.3.8 Dermalproblems 102
4.4 Next-generationprobiotics 104
4.4.1 Geneticallymodifiedorganisms 107
4.5 Conclusion 107
References 108
5. Bacteriocin and itsbiomedical application with special
reference to Lactobacillus 123
RashiMiglani,NagmaParveen,AnkitKumar,SeetaDewali,
GauravRawat,RojitaMishra,AmritaKumariPandaandSatpalSinghBisht
5.1 Introduction 123
5.2 Typesofbacteriocinproducedbylacticacidbacteria 125
5.3 Modeofactionoflacticacidbacteria-bacteriocins 130
5.4 Biomedicalapplications 131
5.4.1 Antitumoractivity 131
5.4.2 Bacteriocininoralandskincare 132
5.4.3 Bacteriocininurinarytractinfectioninfection 133
5.4.4 Otherbiomedicalapplications 134
5.5 Conclusion 136
References 140
6. Microbialbiosurfactants: current trendsand applications in
biomedicalindustries 147
AmritaKumariPanda,SeetaDewali,RashiMiglani,RojitaMishra,
SurajitDeMandalandSatpalSinghBisht
6.1 Introduction 147
6.2 Typesofbiosurfactant 149
6.3 Glycolipids 149
6.4 Rhamnolipids 149
6.5 Trehalolipids 150
6.6 Sophorolipids 150
6.7 Xylolipids 150
6.8 Cellobiolipids 150
viii Contents
6.9 Lipopeptides 151
6.10 Phospholipids 151
6.11 Fattyacidbiosurfactants 151
6.12 Polymericbiosurfactant 152
6.13 Productionofbiosurfactants 152
6.14 Applicationsofbiosurfactants 154
6.15 Antimicrobialactivity 154
6.16 Biosurfactantsasantibiofilmmolecules 155
6.17 Disruptormoleculesmadeoflipopeptidebiosurfactant 156
6.18 Lipopeptidesthatissimilartofengycin 156
6.18.1 Putisolvin 156
6.18.2 Pseudofactin 156
6.18.3 Surfactin 157
6.18.4 Complexesoflipopeptides 157
6.19 Biosurfactantsasdrugdeliveryagents 157
6.19.1 Microemulsion 158
6.20 Biosurfactantsindrugdeliveryapplications:challenges,selection
guidelines,andfutureprospects 159
6.21 Biosurfactants:strengtheningofimmunesystem 160
6.21.1 Effectsofglycolipidbiosurfactantsontheimmunesystem 160
6.21.2 Effectsoflipopeptidesbiosurfactantsonimmunesystem 161
6.22 Antiviralapplications 162
6.23 Vaccinedevelopmentandimmunomodulation 163
6.24 Nanomaterialfordiagnosis 164
6.25 Conclusionsandfutureperspectives 164
References 165
7. Microbes used as anticanceragents andtheirpotential
application inbiomedicine 173
SnigdhaBhardwajandSonamBhatia
7.1 Introduction 173
7.2 Mechanismofcancersuppressionbymicrobes 175
7.3 Microbialbioengineeringforcancertherapy 176
7.4 Differentclassesofmicrobialagentswithanticancerpotential 180
7.4.1 Microbialprotein,peptides,andnonribosomalpeptidesfor
cancertherapy 180
7.4.2 Microbialenzymesandprodrugconvertingenzymes 181
7.4.3 Microbialangiogenicinhibitorsforcancersuppression 182
7.4.4 Microbialquorumsensingregulatorynetworkandbiofilmsfor
cancertherapy 183
Contents ix
7.4.5 Microbialimmuneresponseandsecretionsforcancer
immunotherapy 184
7.4.6 Microbialmetabolitesincancerprevention 186
7.4.7 Microbesincombinationwithconventionalanticancertherapy 194
7.5 Microbesunderwentclinicaltrialsforcancertherapyoverthepast5years 195
7.5.1 Streptococcuspyogenes 195
7.5.2 Clostridiumnovyi 196
7.5.3 SalmonellaentericaserovarTyphimurium 196
7.5.4 MycobacteriumbovisBacillusCalmette-Guerin 197
7.5.5 Magnetococcusmarinus 197
7.5.6 Plasmodiumfalciparum 198
7.5.7 Toxoplasmagondii 198
7.6 Challengesassociatedwithmicrobesusedinanticancertherapy 199
7.7 Conclusion 199
References 200
8. Revealingthe hidden heights of microbialmetabolites on
reproductive physiology 217
DheepthiJayamurali,GowsalyaSaminathan,KrishnapriyaM.Varier,
PadminiSateeshaAcharya,NiveditaManoharan,RajeshwariParasuraman,
BabuGajendranandSathyaNarayananGovindarajulu
8.1 Background 217
8.2 Microbialcontributionstotheenhancementofmalereproductive
physiology 220
8.2.1 Themalereproductivesystem 220
8.2.2 Microbiotaofthemalereproductivesystem 221
8.2.3 Impactofthegutmicrobiomeandaminoacidsinthehost
reproduction 223
8.2.4 Roleofprobioticsinmalefertility 224
8.2.5 Impactofreproductivemicrobiotainmaleinfertility 226
8.3 Microbialcontributionsintheenhancementoffemalereproductive
physiology 227
8.3.1 Introductiontothefemalereproductivesystem 227
8.3.2 Femalereproductivemicrobiome 227
8.3.3 Microbialcontroloffemalereproductivehealth 228
8.3.4 Reproductivemicrobiomeanditsinfluenceonassisted
reproductivetechnologies 235
8.3.5 Probioticssupplementation:therapeuticstrategiestoenhance
reproductivehealth 237
8.4 Conclusion 238
References 239